# US 2024/0003891 A1 · Immunoassay using carbon nanomaterials and method of detecting target antigen using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003891 A1
- Document ID: US20240003891A1
- Status: Published application
- Kind: A1
- Application number: 18/124,986
- Filed: 2023-03-22
- Published: 2024-01-04
- Earliest claimed: 2022-07-01
- Inventors: Ji Hoon LEE
- Web page: https://patentgrep.com/patent/US20240003891A1

## CPC

- G01N 33/582: {with fluorescent label}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- G01N 33/5302: {Apparatus specially adapted for immunological test procedures}
- C07K 2317/55: Fab or Fab'
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosed is a device and a method for detecting a target antigen in a sample, the device includes: a container; a carbon nanomaterial; and an antibody conjugated with a marker, where the antibody is immobilized on a surface of the carbon nanomaterial, where the antibody has a binding site of the target antigen, and where, when the target antigen binds to the binding site of the antibody, the antibody conjugated with the marker detaches from the carbon nanomaterial and the marker-labeled antibody bound with the target antigen generates a signal.

## Claims

### Claim 1

A device for detecting a target antigen in a sample, comprising:
a container;
a carbon nanomaterial; and
an antibody conjugated with a marker,
wherein the antibody is immobilized on a surface of the carbon nanomaterial,
wherein the antibody has a binding site of the target antigen, and
wherein, when the target antigen binds to the binding site of the antibody, the antibody conjugated with the marker detaches from the carbon nanomaterial and the marker-labeled antibody bound with the target antigen generates a signal.

### Claim 2 (depends on 1)

The device of claim 1, wherein the carbon nanomaterial is one or more selected from the group consisting of graphene, graphene oxide, reduced graphene oxide, carbon nanotubes, and carbon nanotube oxides.

### Claim 3 (depends on 1)

The device of claim 1, wherein the antibody is immobilized on the surface of the carbon nanomaterial by a non-covalent π-π stacking interaction, and a distance between the antibody and the carbon nanomaterial is 10 nm or less.

### Claim 4 (depends on 1)

The device of claim 1, wherein the sample is a biological solution selected from the group consisting of serum, plasma, whole blood, sweat, urine, and cerebrospinal fluid.

### Claim 5 (depends on 1)

The device of claim 1, wherein the signal generated from the marker is selected from the group consisting of bioluminescence, chemiluminescence, fluorescence, colorimetric, electrochemical, electrochemiluminescence, radiometric, and light visible to the naked eye.

### Claim 6 (depends on 1)

The device of claim 1, wherein the marker is a bioluminescence marker selected from the group consisting of luciferase, luciferin, and luciferin derivatives.

### Claim 7 (depends on 1)

The device of claim 1, wherein the marker is a chemiluminescence detection marker of a detection selected from the group consisting of acridinium ester chemiluminescence detection, chemiluminescence using horseradish peroxidase (HRP) labeled antibody, chemiluminescence detection using alkaline phosphatase (ALP) labeled antibody, phenylglyoxal derivative chemiluminescence detection, and ODI chemiluminescence detection operated with an antibody conjugated with luminescent dyes.

### Claim 8 (depends on 1)

The device of claim 1, wherein the marker is a colorimetric detection marker of a detection selected from the group consisting of colorimetric detection operated with antigen-bound antibody conjugated with horseradish peroxidase (HRP), colorimetric detection operated with antigen-bound antibody conjugated with alkaline phosphatase (ALP), colorimetric detection operated with antigen-bound antibody conjugated with β-galactosidase, and colorimetric detection operated with antigen-bound antibody conjugated with glucose oxidase.

### Claim 9 (depends on 1)

The device of claim 1, wherein the marker is an electrochemiluminescence detection marker selected from the group consisting of a ruthenium complex (Ru(bpy)32+), a gold nanoparticle, a platinum nanoparticle, a silver nanoparticle, and N-(4-aminobutyl)-N-ethylisoluminol (ABEI).

### Claim 10 (depends on 1)

The device of claim 1, wherein the marker is an electrochemical detection marker selected from the group consisting of horseradish peroxidase (HRP), alkaline phosphatase (ALP), glucose oxidase, and β-galactosidase.

### Claim 11 (depends on 1)

The device of claim 1, wherein the marker is a fluorescence detection marker selected from the group consisting of horseradish peroxidase (HRP), alkaline phosphatase (ALP), and a fluorescence dye.

### Claim 12 (depends on 1)

The device of claim 1, wherein the marker is a naked-eye detection marker selected from the group consisting of horseradish peroxidase (HRP) and alkaline phosphatase (ALP).

### Claim 13 (depends on 1)

The device of claim 1, wherein the marker is a radioactive detection marker of 125I.

### Claim 14 (depends on 1)

A method of manufacturing the device of claim 1, comprising:
fixing the carbon nanomaterial on an inner surface of the container;
providing the antibody conjugated with the marker; and
bringing the antibody conjugated with the marker into contact with a surface of the carbon nanomaterial.

### Claim 15 (depends on 14)

The method of claim 14, wherein the carbon nanomaterial is a magnetic graphene, graphene oxide, reduced graphene oxide, single-walled carbon nanotube, or multi-walled carbon nanotube.

### Claim 16 (depends on 14)

The method of claim 14, wherein the carbon nanomaterial has a form of a thin film composed of graphene oxide, and the container is a polystyrene container.

### Claim 17 (depends on 1)

A method of detecting a target antigen, comprising:
introducing a sample solution to the device of claim 1; and
detecting a signal generated from the marker-labeled antibody bound with the target antigen to detect the target antigen in the sample solution.

### Claim 18 (depends on 17)

The method of claim 17, wherein the carbon nanomaterial is one or more selected from the group consisting of graphene, graphene oxide, reduced graphene oxide, single-walled carbon nanotubes, and multi-walled carbon nanotubes.

### Claim 19 (depends on 17)

The method of claim 17, wherein the carbon nanomaterial has a form of a thin film composed of graphene oxide, and the container is a polystyrene container.

### Claim 20 (depends on 17)

The method of claim 17, wherein the antibody is immobilized on the surface of the carbon nanomaterial by a non-covalent π-π stacking interaction, and a distance between the antibody and the carbon nanomaterial is 10 nm or less.

### Claim 21 (depends on 17)

The method of claim 17, wherein the sample solution is a biological solution selected from the group consisting of serum, plasma, whole blood, sweat, urine, and cerebrospinal fluid.

### Claim 22 (depends on 17)

The method of claim 17, wherein the signal generated from the marker-labeled antibody bound with the target antigen is selected from the group consisting of bioluminescence, chemiluminescence, fluorescence, colorimetric, electrochemical, electrochemiluminescence, radiometric, and light visible to the naked eye.

### Claim 23 (depends on 17)

The method of claim 17, wherein the method does not use an artificially manufactured antigen conjugated with the marker.

### Claim 24 (depends on 17)

The method of claim 17, wherein the method does not use a detection antibody conjugated with the marker.

### Claim 25 (depends on 17)

The method of claim 17, wherein the antibody comprises two or more types of antibodies.

### Claim 26 (depends on 17)

The method of claim 17, wherein the method does not comprise a washing procedure to remove waste after introducing the sample solution to the device.

### Claim 27 (depends on 17)

The method of claim 17, wherein the signal is emitted within 30 minutes after introducing the sample solution containing the target antigen to the device.

### Claim 28 (depends on 1)

A method of quantifying a target antigen, comprising:
introducing a sample solution to the device of claim 1; and
measuring an intensity of the signal to quantify the target antigen in the sample solution.

### Claim 29 (depends on 28)

The method of claim 28, wherein the carbon nanomaterial is one or more selected from the group consisting of graphene, graphene oxide, reduced graphene oxide, single-walled carbon nanotubes, and multi-walled carbon nanotubes.

### Claim 30 (depends on 28)

The method of claim 28, wherein the antibody is immobilized on the surface of the carbon nanomaterial by a non-covalent π-π stacking interaction, and a distance between the antibody and the carbon nanomaterial is 10 nm or less.

### Claim 31 (depends on 28)

The method of claim 28, wherein the sample solution is a biological solution selected from the group consisting of serum, plasma, whole blood, sweat, urine, and cerebrospinal fluid.

### Claim 32 (depends on 28)

The method of claim 28, wherein the signal generated from the marker-labeled antibody bound with the target antigen is selected from the group consisting of bioluminescence, chemiluminescence, fluorescence, colorimetric, electrochemical, electrochemiluminescence, radiometric, and light visible to the naked eye.

### Claim 33 (depends on 28)

The method of claim 28, wherein the method does not use an artificially manufactured antigen conjugated with the marker.

### Claim 34 (depends on 28)

The method of claim 28, wherein the method does not use a detection antibody conjugated with the marker.

### Claim 35 (depends on 28)

The method of claim 28, wherein the antibody comprises two or more types of antibodies.

### Claim 36 (depends on 28)

The method of claim 28, wherein the method does not comprise a washing procedure to remove waste after introducing the sample solution to the device.

### Claim 37 (depends on 28)

The method of claim 28, wherein the intensity of the signal proportionally increases when a concentration of the target antigen in the sample solution increases.

### Claim 38 (depends on 28)

The method of claim 28, wherein the signal is generated within 30 minutes after introducing the sample solution to the device.
